Latest Industry Insights

Technology Networks spoke with Stefan Foser, vice president of global pharma at Bruker, to explore how they integrate instrumentation, software and consumables to support early-stage pharma innovation.

Dr. Tomek Czernuszewicz shares insights on the limitations of traditional delivery techniques and how Revvity is advancing in vivo imaging through AI-powered tools.

We spoke with the developers and manufacturers of the CRISPR gene therapy used to treat KJ Muldoon’s rare genetic condition, CPS1, about how the product was created in just six months.

Today, single-cell technologies are not only dissecting genomic, transcriptomic and proteomic profiles but also enabling dynamic measurements of cellular functions. Bruker's new Beacon Discovery Platform could make this a reality for more labs.

David Curtin discusses how the integration of MALS detectors with Empower software enhances biopharmaceutical QC, aligns with evolving regulatory demands and supports the future of complex biologic product analysis.

Learn more about how AI is advancing the mRNA drug discovery pipeline and what we can expect to see in the future in this interview with Dr. Davide De Lucrezia.

Learn how CD34+ stem cells may help heart attack patients recover. A look at cutting-edge cell therapies and what's coming next in cardiac care.

Discover how induced pluripotent stem cell technology is solving scale and consistency issues in mesenchymal stem/stromal cell therapy manufacturing and learn about Cynata’s ongoing clinical trials.

James Connelly discusses the importance of third-party verification and how recent funding will help accelerate the development of Impact Laboratories' digital sustainability tools.

At the BioTrinity 2025 conference, Technology Networks spoke with Dr. Pedro Correa de Sampaio, co-founder and CEO of Neobe, who are utilizing synthetic biology to engineer bacteria capable of breaking down the barriers within tumors.